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LN is one of the most serious manifestations of SLE. LN affects 30% to 50% of 
all SLE patients,  and it causes end-stage renal disease (ESRD) in 20% of affected 
patients (1). LN associates with 4 folds increase in morbidity and mortality rate 
(2). About 50-60% of adult SLE patients have clinical features of kidney 
involvement during the SLE disease course (3). Other reports noted kidney 
involvement in SLE patients occurs in up to 40% of patients (4). LN occurs 
commonly within 5 years of the SLE diagnosis or sometime later (5). 
Characteristically, LN presents with hypertension, proteinuria, however, chronic 
kidney disease (CKD) and ESRD are not uncommon complications. The first 
presentation of LN is a  reduction of estimated glomerular filtration rate (eGFR) 
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Lupus nephritis (LN) is a serious complication of systemic lupus 
erythematosus (SLE). LN is a leading cause of morbidity and 
mortality in SLE patients. LN presents with various symptoms 
and signs, ranging from asymptomatic renal involvement to End-
Stage Renal Disease (ESRD). The pathogenesis of LN is not 
clearly understood, however, there are extra and intra-renal 
underlying factors that have been postulated in LN pathogenesis. 
Renal biopsy is crucial to stage LN and to rule out other causes. 
Histopathological studies have shown six different types of LN. 
Knowing the histopathological lesion, chronicity and the disease 
activity are essential to plan the LN treatment and to predict the 
outcome. There are different regimens for treating LN. In this 
review, LN pathogenesis and new advances in treatment will be 
briefly reviewed. 
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and/or significant proteinuria >500 mg/day in about 30% of cases. The degree of 
eGFR reduction and proteinuria at presentation may help to predict the severity 
of the histopathological changes (6), however, it is not always precise (7). 
Silent LN occurs, manifesting mostly by an increase of blood pressure with 
normal serum creatinine and urine analysis (8). Renal biopsy is the gold standard 
for LN diagnosis and is needed to assess the histological stage, chronicity, and 
activity that are required before initiating the long-term treatment (9). Despite 
the advancement of SLE treatment, about 20% of LN patients develop ESRD 
commonly after 10 years (10). LN pathogenesis is an immune complex-mediated 
process, however, other factors have an essential role in LN pathogenesis (11). 
The role of complement, autoantibodies, apoptosis, and the adaptive immune 
system in the pathogenesis of LN has been speculated. In this update review, the 





There are worldwide variations in the frequency and prevalence of SLE that 
vary with sex, age, ethnicity, and time that can affect LN epidemiology (12). 
Depending upon the population surveyed, the occurrence and prevalence of LN 
varies (13). 
At presentation, Class II LN is the most prevalent (56%) followed by  Class II 
(26%), and then Class III (18%) (14). It was reported that earlier age of LN 
presentation associates with more severe disease manifestations and earlier 
mortality (15). However, a new Japanese study reported that early-onset LN has 
a better renal response and lower mortality rate during the first year of the 
diagnosis (16). The overall LN incidence was 60% after 5 years of post-SLE 
diagnosis (17). 
LN appears to be more prevalent in certain ethnic groups. It was reported 
that 45% of African Americans, 42% of Chinese, and 30% of Caucasian SLE 
patients had evidence of renal involvement (18). Another multi-ethnic USA 
cohort study reported that renal disease occurred in 51% of Africans and 43% of 
Hispanics and 14% of Caucasians SLE patients (19). Other reports noted that 
31% of new-onset SLE patients had an active renal disease at first presentation 
(18).  
It was reported that kidney outcome and mortality are worse in African and 
Hispanic patients than Caucasian patients, and there are differences in prognosis 
among different ethnicities. Black and Hispanic American patients have the worst 
outcomes, and they commonly progress to kidney failure than white patients (3),. 
Furthermore, the Black and Hispanic patients seem to develop worse 
histopathological changes, more proteinuria, and higher serum creatinine levels 
than white patients at LN diagnosis. Moreover, anti-Sm, anti-Ro, and anti-
ribonucleoprotein autoantibodies that are associated firmly with LN, are more 
often positive in black than white patients (3). The justifications for the racial 
and ethnic differences are not well-understood, however, genetic and 
socioeconomic factors may have a role (3). A study that had compared early-
onset and late-onset LN in an Asian population reported that early-onset LN 
patients had a lower mortality rate than late-onset LN during 6 and 12 months 
follow up (19). Ugolini-Lopes et al reported that there is no significant difference 
in disease severity and long-term prognosis (20). 
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Pathogenesis of LN 
 
LN pathogenesis is essentially related to the site of anti-double-stranded DNA 
antibodies (anti-dsDNA, or anti-DNA) immune deposit formation (21). Anti-
DNA immune complex consists of DNA and anti-DNA, although the immune 
complex may also contain chromatin, C1q, laminin, Sm, La (SS-B), Ro (SS-A), 
ubiquitin, and ribosomes (22). Anti-DNA antibodies can combine directly with 
the glomerular basement membrane (GBM) and mesangium parts (23). If the 
immune deposits occur in the mesangium and subendothelial space, they will be 
adjacent to the GBM and glomerular tuft space. This deposition activates 
complement classical pathway that enhances the chemoattractants (C3a & C5a) 
production, triggering migration of neutrophils and mononuclear cells into 
glomerular tuft space. These changes cause a mesangial or focal or diffuse 
proliferative glomerulonephritis changes which are present by red cells, white 
cells, and cellular and granular casts, proteinuria with rapid renal function 
deterioration. When the immune complex deposits are landed in the subepithelial 
space, it can activate the complement cascade with inflammatory cell influx into 
the subepithelial space, causing nephrotic range proteinuria and membranous 
nephropathy histopathological lesions. Another important determinant of the site 
of the immune complex formation and deposition is related to both the charge of 
the antibody and its antigen-binding region. The antibody may attach to 
antigens at different glomerular capillary wall sites, causing different histologic 
and clinical manifestations (24). Some data suggest that intraglomerular 
membrane-associated nucleosomes are targeted by anti-dsDNA autoantibodies 
(25). There is evidence that some patients have anti-DNA antibodies but no 
nephritis, and Anti-DNA can cause nephrotoxicity without immune complex 
formation. Anti-DNA antibodies can bind to human mesangial cells in vitro and 
induce proinflammatory substances production, increasing the risk of LN (26). 
Neutrophils and neutrophil extracellular entrapment may add to antigen-
specific autoantibody production, inducing inflammation, endothelial damage, 
and interferon-alpha formation inside the renal tissue (6). Furthermore, Immune 
(small i) complex deposition can activate an inflammatory response. Immune 
complex to endothelium can lead to proinflammatory leukocytes recruitment, 
promoting autoimmune injury (27). Activated glomerular cells, infiltrating 
macrophages, and T cells cause inflammatory cytokines, involving tumor necrosis 
factor-alpha (TNF-alpha), interleukin-6 (IL-6), tumor growth factor-beta, 
interferon-gamma, chemokines, and platelet-derived growth factor release (28). 
Additionally, activated platelets induce also mesangial cell proliferation, 
enhancing further damage (29). 
Different genetic factors predispose patients to the development of LN (30). 
There is evidence that LN is more common and severe in certain ethnic 
populations, indicating genetic factors in LN pathogenesis (31–33). Macrophages 
immunoglobulin receptor alleles Fc-gamma-RIIa-H131 polymorphisms have a link 
with susceptibility to LN (33), however, another study reported that there is not 
any link (32). Other reports found strong links between the Fc-gamma-RIIIa-
F158 receptor allele and Fc-gamma-RIIIb polymorphisms and lupus nephritis 
(32,33). Furthermore, LN due to glomerulosclerosis in African Americans has 
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A. Extrarenal pathogenic mechanism (Fig 1) 
 
A-1. Cell Death and Dead Cell Handling 
SLE patients have unusual genetic variants that may alter apoptosis of the 
dead cell (35), the complement system and/or phagocytes (36). Neutrophils 
commence what is called NETosis. Naturally, the neutrophils are removed from 
the circulation after 6-8 hours (37). The inflammatory process activates the 
neutrophil that has diverse complexed functions such as apoptosis that diverts to  
the neutrophil extracellular trap, leading to cell death process called NETosis 
(38). It is thought that the released nuclear particles of the damaged cells are 
recognized as foreign proteins by the immune system in SLE patients. The 
activated immune cells damage most of the body organs including the kidneys, 
causing LN. 
 
A-2. Environmental factors for LN development 
 
Bacterial and viral infections stimulate SLE activity. Bacterial infections cause 
a transient expansion of autoreactive lymphocyte clones and accelerate intrarenal 
immune cells, promoting the severity of proteinuria and kidney damage (39). 
Ultraviolet light in SLE patients causes keratocyte death (40), and estrogen and 
progesterone accelerate the sex hormone-dependent immunoregulatory pathways 
(41). Fig (1) 
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Fig 1. Extrarenal mechanism of Lupus Nephritis 
Lymphocyte (LC), Immature mother cells (I. Cells), Mature mother cells (M cells), B-lymphocyte (BL), Plasma cell (P.C), Interleukins 
(ILS), Auto-Antigen-Specific-T Lymphocytes (AASTC), Auto-Antigen-Specific-Antibodies (AASA). 
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B. Intrarenal Pathogen 
 
B-1 Immune complex 
LN pathogenesis involves an auto- nonspecific activation of B cells, leading to 
immune globulins  formation in the kidney tissues. (42) Furthermore, it seems 
that B cells have pathogenic effects more than antibody formation such as 
autoantigen presentation to the stimulated T cells, and inducing local 
proinflammatory effects (43). 
Mesangial, endothelial, subendothelial and peritubular capillaries immune 
complex deposition site has a significant role of LN severity (44). In class I&II 
LN, the deposition is in the mesangium,  class III and IV LN at the endothelial 
regions, and in class V, the immune complexes deposition is in the subepithelial 
tissues (45).  
Anti-DNA antibodies from the damaged cells activate endothelial and 
mesangial cells via different mechanisms. The formed antibodies are directly 
engulfed by renal cells. This process involves cross-reactivity with a-actinin or 
annexin II on mesangial cells (46), damaging the interstitial cells, however, this 
theory was not supported by some reported data (47). It was reported that 
complement activation and its released factors lead to immune complex 
deposition, promoting inflammation and immunopathology reactions, 
opsonization, and lupus autoantigens removal from the extracellular space. All 
these responses are reduced in complement system deficiency (48).   
Immunostimulatory nucleic acids stimulate the glomerular endothelium, 
mesangial cells, and macrophages to produce large amounts of proinflammatory 
cytokines and IFN-a and IFN-b (49). The significance of IFN intraglomerular 
signaling is not well understood, although it can cause kidney damage in the LN, 
leading to changes in tubuloreticular structures. These tubuloreticular changes 
may lead to ultrasonic changes in about 95% of NL patients. These ultrasound 
changes are abnormal renal size and change in cortical echogenicity, correlating 
perfectly with the degree of kidney damage caused by LN (50). 
 
B-2. Repair of the damaged tissue  
Progression of CKD in LN is related to degree of renal parenchymal cell 
damage, and the amount of renal fibrosis. Focal glomerular tuft necrosis causes 
parietal epithelial cells migration into the glomerular tuft that forms an 
extracellular matrix, producing FSGS which may progress to global 
glomerulosclerosis (51). Parietal cell stimulation by mitogens as fibrinogen 
accounts for cellular glomerular crescent formation to occupy the urine space by 
uneven glomerular tuft cells proliferation (52). In stage V LN, the parietal 
epithelial cells polarity is lost due to the increased honeycombing of Bowman’s 




Histopathological classification of LN 
 
Renal biopsy is needed to know which class the patient has and to plan the 
treatment. Despite the diversity of recommendations and the indications of renal 
biopsy in LN, some authors commending to carry out the renal biopsy if there is 
not contraindications (53).  During 2004, nephrology, pathology, and 
rheumatology scientists tried to agree upon a uniform classification for LN. The 
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classification seems more informative than the 1982 modified WHO classification 
(44). Six different histological lesions of LN were proven by the International 
Society of Nephrology (ISN) classification system. It was reported that serological 
and sedimented urine markers may give a hint to the underlying histological 
changes, however, none of these markers eliminate the significance of the renal 
biopsy to assess the chronicity and activity of the LN (54).  
 
A. Class I (Minimal mesangial LN)  
This lesion affects primarily children generally in non-SLE patients. In SLE 
patients, this class is not usually diagnosed early, because it usually presents with 
mild transient proteinuria or even normal urine analysis. These patients rarely 
require renal biopsy. Histologically, there are mesangial immune complex deposits 
that are immunofluorescent positive, and these deposits can be detected only by 
electron microscopy.  
 
B. Class II (Mesangial proliferative lupus nephritis)  
Mesangial hypercellularity (of any degree) and/or mesangial matrix 
expansions are detected by light microscopy. By electron microscopy, there are 
subepithelial or subendothelial deposits. Class III (Focal LN)  
This class is subdivided into focal and diffuse. When half or less of the 
biopsied glomeruli are involved then known as focal LN type, whereas diffuse 
class III subtype has > 50% of glomeruli are affected by light microscopy 
examination. Immunofluorescence microscopy (for IgG and C3) reveals almost 
uniform involvement in >50% glomerular damage (55). Hematuria and 
proteinuria, hypertension, reduced eGFR, and/or nephrotic syndrome are usually 
present in different combinations.  
 
Class IV (Diffuse LN) 
Class IV lupus nephritis is the worst histologic type of LN. Microscopically, 
there are glomerular and interstitial lesions with varied degree of sclerosis as well 
fibrosis. Reduced eGFR, proteinuria and hypertension with generalized oedema 
might be the presenting features. 
  
E. Class V (membranous LN)  
In this class, massive proteinuria and features of nephrotic syndrome are 
characteristic presentations (56). Histologically, there is a characteristic diffuse 
thickening of the glomerular capillary wall on light microscopy with subepithelial 
immune deposits (either global or segmental involvement) on immunofluorescence 
or electron microscopy.  
 
F. Class VI (Advanced sclerosing LN)  
Class VI is characterized by generalized glomerular sclerosis in > 90% of the 
glomeruli. It is the result of all classes of LN progression. Patients have usually 
slowly progressive renal function impairment with proteinuria and almost normal 
urine routine sediment. Identification of this class of lesions is essential, while it 
will not benefit from immunosuppressive therapy.   
LN is a heterogeneous disease and may present with different combinations of 
clinical and laboratory features. Each LN patient has his/her variable features, 
but notably, different clinical settings and histopathological patterns may present 
in a single patient during the disease progression.  
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Treatment of LN 
 
The published treatment regimens of LN by the European League Against 
Rheumatism (EULAR)/European Renal Association-European Dialysis and 
Transplant Association (ERA-EDTA) aimed for a full renal response during 12 
months, although, more than 12 months of treatment might be required when the 
proteinuria presents before initiating the treatment (53). Despite the negative 
effects of age, sex, ethnicity, and histological findings, LN complete response to 
the immunosuppressive drugs was reported at 6 and/or 12 months, leading to 
better renal outcomes and less mortality rate (8,16). In general, in recent 
decades, while the prognosis of LN has improved due to the availability of 
advanced diagnostic and treatment facilities (6), there are still therapeutic 
challenges. A collaborative approach between rheumatology and nephrology 
teams is necessary to obtain better results. LN treatment response is clinically 
defined and usually stratified into complete, partial, and no response (3). 
Immunosuppressive therapy is usually required for patients with active diffuse 
and focal proliferative LN (class III&IV LN) (57), but in class I and minimal 
mesangial and mesangial proliferative LN is not always indicated. The prognostic 
and therapeutic responses depend on the degree of LN activity (active 
inflammation) and chronicity (glomerular scarring, tubulointerstitial fibrosis, and 
atrophy), although it is usually not applicable in all cases (57). Some reports 
have shown differences in LN severity and LN outcomes between black African-
American or Afro-Caribbean and Hispanic populations compared to non-Hispanic 
white patients, as well as the response to immunosuppressive treatment (19,58). 
 
Table 1. Features of Chronicity and Activity of Lupus Nephritis. 
Disease activity Disease chronicity 
                                               A-Glomerular changes  
1. Endocapillary hypercellularity +/- leukocyte infiltration and 
decreased the lumen of the capillary  
1. Glomerular sclerosis (segmental or global) 
 
2. fibrinoid necrosis  & Karyorrhexis  2. Cellular crescents 
3. Crescents formation   
4. Intraluminal immune aggregates & subendothelial deposits 
that can be detected by light microscope 
 
5. Damage and tear GBM, plus glomeruli leucocyte infiltration  
                                              B-tubulointerstitial changes  
Mononuclear cell infiltration 1. Interstitial fibrosis 




LN patients are generally hypertensive, and good hypertension control is 
important to prevent further renal damage and to improve protein loss. The 
common antihypertensives used to achieve these effects are angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin II receptor inhibitors 
(BARs). In addition, diet changes have an important effect on lowering blood 
pressure and controlling hyperlipidemia.  
It is essential to avoid nephrotoxic agents such as nonsteroidal anti-
inflammatory agents (NSAIDs) to limit further kidney injury. Pregnancy is a 
trigger for worsening of kidney function in LN patients, and pregnancy should be 
avoided especially when the SLE is active because some medications might be a 
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teratogen (59), and the risk of abortion is high. Consequently, a woman should 
not conceive during SLE active status which requires these teratogenic agents. 
For a woman who insists on pregnancy, approaching close follow-up care and 
frequent kidney function tests are necessary (60).  In addition, other associated 
systemic manifestations of SLE should be managed with agents that do not 
adversely affect the kidneys. 
 
A. Immunomodulation drugs 
Hydroxychloroquine (HCQ) 
Some reported data indicate that HCQ enhances NT outcomes. HCQ reduces 
the risk of the tubulointerstitial inflammation (61), and complete response was 
noted during one HCQ treatment (62). LN progression to CKD and/or ESRD is 
significantly reduced with HCQ treatment. It was reported that removal of HCQ 
from the management plan of LN associates with 2 folds increase of death or 
ESRD or renal flare or requirement for rescue therapy during the LN 
management maintenance phase (63).  
 
B. Immune suppressive therapy (table 1) 
1.Corticosteroid  
Steroids are utilized over a long period of time, they have proven an 
important long-term beneficial effect on their own, and especially in combination 
with other immunosuppressants such as cyclophosphamide. Nearly all patients 
with LN with active disease require a combined intravenous steroid and 
cyclophosphamide for inducing remission.  
Although steroids are the mainstay of LN management, cyclophosphamide, 
azathioprine, mycophenolate, and other immune-suppressive drugs are sometimes 
added. In aggressive proliferative glomerulonephritis induced LN, aggressive 
combined therapy improves the renal outcome  (64). Side effects of steroids such 
as osteoporosis should be sought and treated promptly by calcium, 
bisphosphonate, and vitamin D in some cases.  
Minimum mesangial LN (Class I) does not require specific treatment, while 
Class II lupus nephritis may require treatment if proteinuria is greater than one 
gram/day. On the contrary, class III and IV patients are more likely to progress 
to ESRD, so they need aggressive treatment with immunosuppressive 
medications. Prednisone can be tried from 1 mg/kg/day for a minimum of 4 
weeks and then gradually reduced based on clinical response. Most of these 
patients require 5-10mg/day of maintenance for approximately 2 years. 
Methylprednisolone intravenously at a maximum dose of 1000 mg/day for 3 days 
can be used in critically ill patients, followed by prednisolone orally. Patients who 
do not respond to corticosteroids alone and/or have unacceptable side effects to 
corticosteroids, adding others agents such as  mycophenolate or azathioprine or 
others must be tried (3). Furthermore, patients have  a worsening renal function, 
and/or have severe proliferative lesions, and/or evidence of sclerosis in renal 
biopsy specimens, a combination of steroid with another two immunosuppressive 
drugs are advisable (3). Long term use of high doses of steroids can cause weight 
increase, diabetes, hypertension, acne, facial swelling, edema, cushingoid 
appearance, psychosis, etc (3).  
 
2.Azathioprine, Mycophenolate and Cyclophosphamide 
Cyclophosphamide and azathioprine are equivalent, but cyclophosphamide is 
most effective in preventing ESRD following LN proliferation. Mycophenolate 
mofetil can be used on its own or sequentially after 6 months of IV treatment of 
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cyclophosphamide (65). Mycophenolate mofetil is less toxic and is effective as 
cyclophosphamide IV to prevent the progression of Class III and IV LN to ESRD 
(65). 
Cyclophosphamide is typically given on monthly basis either as a single bolus 
or 2 divided doses for 6 months. Every 3 months reassessment of the clinical and 
laboratory responses is often done. Cyclophosphamide dose should be calculated 
according to renal function to reduce the risk of the side effects.  
Cyclophosphamide causes ovarian failure, therefore, gonadotropin-releasing 
hormone analog (leuprolide acetate) is given in females LN patients who are 
treated by cyclophosphamide, to prevent cyclophosphamide-induced ovarian 
failure (66).  
Azathioprine can also be used as a second-line agent, although some 
nephrologists are using it as a first-line drug. It was reported that the response to 
mycophenolate mofetil was better than to azathioprine for LN relapse prevention 
in patients who had smooth induction therapy cycles (67). However, a 10-year 
follow-up of the MAINTAIN Nephritis Trial concluded that azathioprine and 
mycophenolate mofetil as maintenance therapy in proliferative LN gave an equal 
response (68). Although azathioprine and Mycophenolate may have the same 
effect in LN management, the follow-up, side effect, and cost must be considered 
(69).  
Membranous LN (class V) patients are usually treated with prednisone for 1-3 
months, then start tapering, then continue for 1-2 years if a response occurs. A 
study reported that azathioprine, cyclosporine, cyclophosphamide, mycophenolate 
mofetil, and chlorambucil are all effective in reducing proteinuria (70). 
 
3.New agents under trial 
Rituximab reduces B-lymphocytes count and activity (71). Rituximab was 
found effective in steroid resistance LN (72).  A prospective observational single-
center cohort study reported that the steroid-sparing regimen of rituximab and 
mycophenolate mofetil efficacy for LN was effective in maintenance therapy after 
one year  (73). On the contrary, another study did not report a significant 
difference between rituximab and placebo, and rituximab  effect was more 
effective in African American and Hispanic LN patients (74).  Rituximab reduced 
serum anti-DNA antibodies and C3 and C4 level in active proliferative LN, 
although it did not change the clinical outcomes after 1 year of treatment (75). 
Anti-CD20 monoclonal antibodies such as ofatumumab and ocrelizumab were 
tested in experimental studies in treating LN.  The overall renal response was not 
statistically better than the placebo group (76).  
Voclosporin ( novel calcineurin inhibitor) plus mycophenolate mofetil and low-
dose oral corticosteroids reported a partial response in the majority, and complete 
remission in about 30% of acute LN patients (77).  It was reported that oral 
voclosporin effectiveness and safety were significantly higher with lower death 
rate, and proteinuria during one year treatment (78). Tacrolimus is another 
calcineurin inhibitor was reported effective in LN treatment, although most of the 
reported studies were form Asian patients, however, these agents were not 
thoroughly investigated for the long-term benefits and disadvantages (79). 
Atacicept and Abetimus decrease the B lymphocytes and immunoglobulin 
levels in SLE patients (80). Abetimus is a B-lymphocyte tolerogen, and it is 
effective in preventing LN flares in a large, controlled trial, but it did not reduce 
the anti-DNA antibodies serum level (81).  
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Anticytokine therapies including monoclonal antibodies that are directed 
against Interferon-α, IL-1,6,10, and tumor necrosis factor-alpha (TNF-α) are 
preliminary effective in LN treatment, although further studies are needed (82).  
Patients with stage V and VI lupus nephritis, as well as those who develop 
ESRD, global sclerosis, and a renal biopsy-based chronicity index, generally do 
not require aggressive immunotherapy. The best treatment modalities for these 
groups of patients include treating the extrarenal features of SLE and renal 
replacement therapy (RRT).  
 
Table 2. Summary of clinical and laboratory features, treatment options, and prognosis concerning the classes of LN. 
Class Clinical & laboratory presentation  Treatment options Prognosis 
I Asymptomatic, or No specific treatment Excellent  
Mild LL edema 
Normal renal function and GFR  
II  Asymptomatic, or LL edema and may be 
mild high Bp 




Very good if Bp 
controlled and other 
SLE treatments are 
given 
Normal renal function,  microscopic  
hematuria, or mild proteinuria 
If massive proteinuria, podocytopathy 
should be excluded 
-Massive proteinuria: ACE or 
ARAB  
-Steroids and MMF or 
cyclophosphamide if steroid will be 
continued for 6months or more  
III  Red frothy urine, LL edema, and Bp may 
be increased 
Steroids alone or in combination 
with cyclophosphamide or/and 
MMF 
 
Usually, a good 
response and sustained 
remission occurs Proteinuria and hematuria 
Some patients have features of nephrotic 
syndrome and deranged renal function, 
reduced GFR 
Marked reduction of GFR depends on the 
percentage of glomeruli affected.  
Features of class IV LN features occur 
IV  Red urine, LL edema, significant reduction 
of GFR, and/or high Bp 
The same regime as for Class III Usually, there is a 
good response, but 
relapse occurs, 
multiple cycles may be 
required 
Haematuria,  
Proteinuria +/- nephrotic syndrome range, 
increased urea and creatinine 
High anti-dsDNA titer and low serum C3, 
C4  
Acute renal failure may occur 
V Change urine color, LL edema, high Bp Steroid alone or with cyclosporine, 
MMF, or Azathioprine 
Proteinuria improves, 
and progression to 
stage VI can be 
delayed 
Proteinuria +/- nephrotic syndrome, 
normal renal function, and 
microhematuria. 
Mild immunological activity changes 
VI High Bp, features of CKD  A. If chronic changes, no specific ESRD 
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Continuing GFR reduction with 
proteinuria and normal urinary sediment 
treatment. 
B. If acute deterioration is going on,  
Trial of steroid plus one of the other 
immunosuppressive agents can be 
tried 
(BP: blood pressure; LL: lower limbs; MMF: mycophenolate; +/-: with or without; CKD: chronic kidney disease; ESRD: end-stage renal disease; LN: 
lupus nephritis) 
 
Non-Pharmacological Management of ESRD in LN 
 
1.RRT 
In general, HD improves the clinical and serological disease activity as well as 
reduces the need for immunosuppression especially in black patients (83). HD is 
preferred over PD in LN induced ESRD. Several studies have documented that 
high dsDNA antibodies, thrombocytopenia, and higher steroid requirements are 
common among patients on PD. HD has an anti-inflammatory effect, and it 
reduces T-helper lymphocyte count (84). SLE flare-up is hidden and is not severe 
in hemodialyzed SLE patients, however, rash, arthritis, serositis, fever, and 
leukopenia occur, and need specific treatment, therefore, careful and frequent 
follow up are needed in these patients (85). 
 
2.Renal transplantation 
In the USA 3% of the transplanted patients are LN-induced ESRD patients. 
Before transplantation, it is essential to ensure that SLE is in remission status, 
and three months period of dialysis is usually advisable. It is well documented 
that the transplanted kidney in LN patients survives less than the kidney 
transplanted in patients without LN, and the patient outcome is better with 
living-related than the cadaveric allografts, although it can be conducted from 
cadaveric and non-related live donor with reasonable improvement of outcome 
(86). The reasons for the early graft failure in LN are not clear enough, however, 
they are probably due to LN reoccurrence and/or concomitant antiphospholipid 





SLE is a multisystem disease, that may affect the kidneys, leading to 
unrecognized kidney involvement in one side of the scale and ESRD on the other 
side of the scale. The pathogenesis of the LN is not well explained; however, renal 
and extra-renal mechanisms have been postulated as contributors for LN 
pathogenesis. It seems that auto-immune mechanism(s) is/are the most probable 
cause, however, environment, diet habits, and other risk factors might be 
responsible for the pathogenesis and LN progression. Numerous treatment 
regimens have been proposed and tested with varying results that either support 
or discourage their use. RRT and renal transplantation are advisable in ESRD, 
however, further studies are needed to assess their effect on survival and outcome 
in LN. Besides, further studies are needed to explore the pathogenesis to develop 
effective strategies for the prevention and control of LN. LN management has 
improved in recent decades, but the critical need for consensual outcome 
measures remains to be analyzed and triaged. 
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